Trastuzumab has been recognised as an effective therapy for women with HER2 positive breast cancer for several years, and a Cochrane Review on the effects for women with early stage disease was published in 2012. This was joined in June 2014 by a review of the drug’s effects for more advanced cancer. Sara Balduzzi from the University of Modena and Reggio Emilia in Italy describes these findings.